YOLFTbeta
Serina Therapeutics Inc

Serina Therapeutics Inc

SER · AMEX · Healthcare / Biotechnology

1.39USD-0.02 (-1.42%)

Price History

Full chart

Market Stats

Previous Close1.41
Open1.35
Day Range1.35 – 1.52
52-Week Range1.22 – 5.83
Volume10.80K
Market Cap51.05M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.87
Dividend Yield0.00%
Beta0.09
50-Day Avg2.40
200-Day Avg2.18

About

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Steven A. Ledger
  • Employees16
  • Headquarters601 Genome Way, Huntsville, AL, United States, 35806, USA
  • Websitehttps://serinatherapeutics.com

Leadership

  • Dr. Balkrishan Gill Ph.D.Executive Co-Chairman of the Board · b. 1965
  • Mr. Steven A. LedgerCEO & Director · b. 1959
  • Dr. J. Milton Harris Ph.D.Co-Founder, Director Emeritus & Chair of Scientific Advisory Board · b. 1941
  • Dr. Srini Tenjarla Ph.D.Chief Technical Operations Officer · b. 1962
  • Dr. Randall W. Moreadith M.D., Ph.D.Chief Development Officer · b. 1955
  • Mr. Gregory S. CurhanChief Financial Officer · b. 1962
  • Dr. Joshua Thomas Ph.D.Head of Chemistry

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.67M1.40M1.40M1.73M54.00K3.46M500.00K3.15M56.00K130.00K
Growth (%)--15.73%-0.57%+23.78%-96.88%+6316.21%-85.57%+530.60%-98.22%+132.14%
Cost of Revenue911.00K685.00K841.00K998.50K1.28M3.80M145.00K90.00K194.00K85.00K
Gross Profit755.00K719.00K555.00K729.50K-1.23M-333.84K500.00K3.06M-138.00K45.00K
Gross Margin45.32%51.21%39.76%42.22%-2272.22%-9.64%100.00%97.15%-246.43%34.62%
Operating Expense13.49M9.14M11.00M13.29M9.18M1.30M2.77M6.19M16.91M24.07M
Operating Income-12.74M-8.42M-10.45M-12.56M-10.41M-1.63M-2.27M-3.13M-17.05M-24.02M
Operating Margin-764.65%-599.50%-748.21%-726.79%-19272.22%-47.09%-454.07%-99.24%-30442.86%-18478.46%
EBITDA-11.89M-7.74M-7.20M-11.29M-8.74M-1.23M-2.60M5.92M-10.49M-18.91M
EBITDA Margin-713.93%-550.93%-515.47%-653.07%-16185.19%-35.45%-520.99%187.66%-18726.79%-14546.92%
Net Income-15.49M-6.58M-7.50M-12.15M-10.87M-1.26M-2.68M5.27M-11.14M-19.18M
Net Income Margin-929.89%-468.66%-537.39%-703.36%-20120.37%-36.50%-536.42%167.11%-19894.64%-14755.38%
R&D7.87M5.27M5.35M5.35M3.58M3.80M1.57M2.39M7.48M13.15M
R&D as % of Total Revenue472.51%375.14%383.45%309.38%6633.33%109.64%314.62%75.74%13357.14%10119.23%
Interest Expense25.00K12.00K--404.00K3.09K15.88K558.00K526.00K213.00K
Interest Expense % of Total Revenue1.50%0.85%--748.15%0.09%3.18%17.70%939.29%163.85%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.22M9.63M10.67M7.44M3.92M3.15M3.24M8.97M6.72M6.95M
Total Liabilities25.60M1.31M2.44M4.83M9.32M15.03M20.56M41.26M6.22M6.99M
Total Equity-23.42M7.28M7.45M2.22M-5.12M-11.83M-17.21M-32.29M641.00K-37.00K
Cash259.00K7.38M6.71M2.35M527.00K584.00K645.00K7.62M3.67M3.06M
Total Debt---1.96M6.30M13.20M18.12M3.44M268.00K196.00K
Net Debt-259.00K-7.38M-6.71M-396.00K5.77M12.62M17.48M-4.17M-3.40M-2.86M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.43M-6.29M-8.00M-10.16M-7.82M-2.25M-2.08M-2.48M-17.14M-17.95M
Investing Cash Flow-28.00K5.00K1.33M-361.00K-20.00K823.32K980.94K-504.00K-22.00K-59.00K
Financing Cash Flow7.25M13.28M6.00M6.26M5.96M1.08M1.31M10.07M13.21M17.41M
Capital Expenditure23.00K1.00K1.89M641.00K20.00K108.43K9.68K504.00K22.00K59.00K
Free Cash Flow-8.45M-6.29M-9.89M-10.80M-7.84M-2.36M-2.09M-2.98M-17.16M-17.95M
FCF to OCF100.27%100.02%123.68%106.31%100.26%104.82%100.47%120.36%100.13%100.00%

Earnings

Report DateJul 19, 2018Oct 22, 2018Dec 31, 2018Apr 1, 2019Aug 14, 2019Nov 14, 2019Mar 30, 2020May 14, 2020Aug 14, 2020Nov 16, 2020Mar 31, 2021May 17, 2021Aug 13, 2021Nov 12, 2021Mar 29, 2022May 13, 2022Aug 12, 2022Nov 10, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 22, 2024May 14, 2024Aug 9, 2024Nov 11, 2024Mar 20, 2025May 8, 2025Aug 11, 2025Nov 13, 2025Mar 30, 2026May 14, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate0.000.00-----------------------0.42-0.62-0.42-0.53-0.50-0.44-0.35-
EPS Actual-0.01-0.05-3.13-0.09-0.08-0.09-0.07-0.08-0.07-0.07-0.06-0.05-0.07-0.05-0.06-0.07-0.07-0.06-0.07-2.47-5.01-3.20-3.380.510.13-0.36-0.49-0.66-0.51-0.31-0.53-0.55-
Surprise--------------------------184.79%20.97%-57.14%3.77%38.00%-20.45%-57.14%-
Timing---------------------After-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-market-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap51.05M
Enterprise Value35.81M
Trailing P/E0.00
Forward P/E0.00
Price / Sales323.02
Price / Book2.97
EPS-1.87
Book Value0.737
Revenue (TTM)0
Gross Profit (TTM)-14.07M
EBITDA-25.59M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-207.94%
Return on Assets-92.30%
Shares Outstanding25.40M
Shares Float11.15M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 9.50
  • Strong Buy
    1

Stock Splits

  • Mar 15, 202428:1000